Initial Treatment Approach for Gastrointestinal Neuroendocrine Tumor (GNET) Sarcoma

Diagnostic Confirmation and Staging

The European Society of Medical Oncology recommends complete histopathological confirmation, including immunohistochemical markers and Ki-67 proliferation index for proper grading, for patients with GNET sarcoma 3, 4
Comprehensive imaging evaluation should include CT and MRI for anatomical localization and staging, as well as somatostatin receptor imaging to detect somatostatin receptor expression, for patients with GNET sarcoma 4
Baseline biochemical tests, including chromogranin A and 5-HIAA, are recommended for patients with GNET sarcoma 5, 6

The American Society of Clinical Oncology recommends complete surgical resection with curative intent as the standard of care for patients with localized GNET sarcoma 1, 7
For tumors <2 cm, the risk of metastasis is lower, but surgical resection is still recommended, according to the National Comprehensive Cancer Network 1
The European Society of Medical Oncology recommends surgical approach, including complete removal of primary tumor with negative margins, regional lymph node dissection, and assessment for synchronous tumors, for patients with GNET sarcoma 1, 7
If potentially resectable metastatic disease, consider surgical resection if complete removal is feasible, as recommended by the American Society of Clinical Oncology 5, 6
Combined approaches using resection and ablative techniques may be considered for patients with locally advanced or metastatic GNET sarcoma, according to the European Society of Medical Oncology 8

For functioning tumors with carcinoid syndrome, prophylactic administration of octreotide is recommended 12 hours before and 48 hours after surgery to prevent carcinoid crisis, as recommended by the American Heart Association 1, 7
Avoid medications that release histamine or activate the sympathetic nervous system during surgery, as recommended by the American Society of Anesthesiologists 1
For patients with liver metastases who are undergoing abdominal surgery and likely to receive long-term somatostatin analog therapy, cholecystectomy should be considered, according to the American Gastroenterological Association 5, 6

Regular follow-up with biochemical markers and conventional imaging every 3-6 months for G1/G2 tumors and every 2-3 months for G3 tumors is recommended by the National Comprehensive Cancer Network 4
Somatostatin receptor imaging is recommended after 18-24 months if somatostatin receptor expression is confirmed, as recommended by the European Society of Medical Oncology 4